Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

BACKGROUND: Outcomes of younger acute myeloid leukaemia patients have moderately improved. Blocking PD-1/PD-L1 pathways enhances anti-leukaemia responses by enabling T-cells in murine models. We hypothesized that adding nivolumab to frontline therapy may decrease the risk of relapse. METHODS: Patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: Ravandi, Farhad, Assi, Rita, Daver, Naval, Benton, Christopher B, Kadia, Tapan, Thompson, Philip A, Borthakur, Gautam, Alvarado, Yesid, Jabbour, Elias J., Konopleva, Marina, Takahashi, Koichi, Kornblau, Steven, DiNardo, Courtney D., Estrov, Zeev, Flores, Wilmer, Basu, Sreyashi, Allison, James, Sharma, Padmanee, Pierce, Sherry, Pike, Allison, Cortes, Jorge E., Garcia-Manero, Guillermo, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6778960/
https://ncbi.nlm.nih.gov/pubmed/31400961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(19)30114-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados